Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases
Alzheimer’s disease and related dementias affect more than 5 million Americans. Unfortunately, few validated pathophysiological biomarkers currently exist and they often require expensive imaging tools or body invasive sampling – which is inadequate for use in large populations.
Although genomics research provides some understanding of disease risk, a multiomics approach is the best way to determine novel biomarkers and therapeutic targets. However, existing proteomic technologies such as mass spectrometry are not always able to measure less abundant proteins.
This whitepaper presents a high throughput, sensitive platform for identifying proteins that may be involved in disease pathology.
Download this whitepaper to learn more about:
- The advantages of blood-based biomarkers
- Using plasma proteins to understand neurodegeneration and vascular pathology
- Using plasma proteomics to assess dementia risk